What do systematic reviews say?

Oral antibiotics vs IV antibiotics

The review found no eligible studies for this question.

• Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Nebulised antibiotics vs IV antibiotics

The review found no eligible studies for this question.

• Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Inhaled antibiotics vs IV antibiotics

• Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 18 participants
  Very low

Summary of findings: Inhaled antibiotics plus IV antibiotics vs IV antibiotics

Summary of findings: Inhaled antibiotics plus IV antibiotics showed no clear difference in quality of life: number of participants achieving MCID compared with IV antibiotics only (low certainty).

• Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis 2022 · Cochrane Headline outcomes only
  RR 1.2 [0.61, 2.34]
  1 study · 16 participants
  Low

Oral plus nebulised antibiotics vs oral antibiotics plus nebulised placebo

• Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 25 participants
  Very low

Summary of findings: anti‐pseudomonal antibiotics vs placebo

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 245 participants
  Low

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

• Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  GRADE not reported

Single vs combination IV antibiotics

The review found no eligible studies for this question.

• Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

The review found no eligible studies for this question.

• Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: cycled vs culture‐based antibiotic therapy

The review found no eligible studies for this question.

• Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin

The review found no eligible studies for this question.

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: tobramycin for inhalation powder vs tobramycin

The review found no eligible studies for this question.

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Oral azithromycin vs placebo

• Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 177 participants
  Moderate

Summary of findings: levofloxacin for inhalation solution vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 282 participants
  Low

Intervention not reported

• Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 38 participants
  Moderate

Summary of findings: amikacin liposome inhalation suspension (ALIS) vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 294 participants
  Moderate

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 374 participants
  Low

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 90 participants
  Low

Summary of findings: aztreonam lysine for inhalation vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 268 participants
  Moderate